Description

Letrozole

Nonsteroidal Aromatase Inhibitor Research Compound

Letrozole is a potent, selective, nonsteroidal aromatase inhibitor (AI) extensively studied for its ability to suppress estrogen biosynthesis through inhibition of the aromatase enzyme (CYP19A1).

By limiting the conversion of androgen precursors into estrogens, letrozole is widely used in laboratory and pharmacological research involving estrogen regulation, endocrine signaling, aromatase activity, and hormone-responsive biological pathways.

How Letrozole Works

Aromatase is the enzyme responsible for key steps in estrogen biosynthesis, including the conversion of testosterone into estradiol and androstenedione into estrone.

Letrozole binds to the aromatase enzyme and reversibly inhibits its activity, reducing the production of estrogens.

This mechanism makes letrozole relevant to research involving:

• Aromatase inhibition
• Estrogen biosynthesis
• Estradiol regulation
• Androgen-to-estrogen conversion
• Endocrine signaling
• Hormone-responsive cellular pathways

Key Characteristics

Potent Aromatase Inhibition
Letrozole is recognized as a highly potent third-generation aromatase inhibitor and has been extensively characterized in both laboratory and clinical research.

Nonsteroidal Structure
Letrozole is classified as a nonsteroidal aromatase inhibitor, distinguishing it mechanistically from steroidal aromatase inhibitors such as exemestane.

Extended Half-Life
Letrozole has an approximate terminal elimination half-life of 2–4 days, supporting prolonged pharmacological activity.

Well-Characterized Pharmacology
Extensive scientific literature exists regarding letrozole’s pharmacokinetics, aromatase inhibition, endocrine effects, and hormone-dependent biological activity.

Research Areas

Letrozole has been investigated in research involving:

• Aromatase enzyme activity
• Estrogen synthesis and metabolism
• Estradiol regulation
• Endocrine feedback mechanisms
• Androgen/estrogen balance
• Hormone-responsive cellular pathways
• Breast cancer biology
• Reproductive endocrinology
• Ovarian physiology
• CYP19A1 research

Compound Information

Compound: Letrozole
Compound Class: Nonsteroidal Aromatase Inhibitor
Molecular Formula: C₁₇H₁₁N₅
Molecular Weight: 285.31 g/mol
Approximate Half-Life: 2–4 days
Primary Target: Aromatase (CYP19A1)

Letrozole vs. Anastrozole

Both letrozole and anastrozole are third-generation, nonsteroidal aromatase inhibitors that reduce estrogen synthesis through inhibition of CYP19A1.

One notable difference is their pharmacokinetic profile. Letrozole generally has a longer elimination half-life, while both compounds have been extensively studied for their ability to produce substantial aromatase inhibition.

Both differ from exemestane, a steroidal aromatase inhibitor that irreversibly inactivates the aromatase enzyme.

Notice & Acknowledgement